Insti drugs

The antiviral drugs most commonly recommended for ART include an INSTI (Figure 1) and two nucleoside/nucleotide reverse transcription (RT) inhibitors (NRTIs), or, in some cases, an INSTI, an NRTI, and a nonnucleoside RT inhibitor (NNRTIs).

2 NRTI 1 INSTI 1 PI . This is a generic educational information sheet for 2 NRTI 1 INSTI 1 PI regimens. Overview. 2 NRTI 1 INSTI 1 PI regimens are generally regimens of 3-4 active drugs that are not routinely used in treatment-na ve or treatment-experienced patients and are only used in specific circumstances.

Choice of INSTI. In the Adult and Adolescent ART Guidelines, two of the INSTIs (bictegravir and dolutegravir) are included as the anchor drug

by AV Zhao 2024 Cited by 58Although INSTIs are generally associated with fewer DDIs compared to other ARV classes such as NNRTIs and PIs, co-administration of INSTIs with

Advantages of these INSTIs include their high genetic barrier to resistance, limited drug-drug interactions, excellent rates of virologic suppression, and favorable tolerability. Few INSTI resistance-associated mutations have been reported in clinical trials involving dolutegravir, bictegravir and cabotegravir.

by XZ Zhao 2024 Cited by 46drugs of the INSTI family. Summary: Recent mutations selected in vitro with second-generation INSTIs suggest the existence of low levels of

Based on the current practice guidelines, INSTI-based regimens are considered as one of the first-line therapies for treatment-na ve HIV-infected patients. There are new INSTIs in development to improve the resistance profile and to decrease the frequency of drug administration.

Major Integrase Inhibitor (INSTI) Resistance Mutations The table lists the most common clinically significant INSTI-resistance mutations.

ARV drugs and concomitant medications may be inducers, inhibitors, and/or substrates of these enzymes. The uridine diphosphate glucuronosyltransferase (UGT) 1A1 enzyme is the primary enzyme responsible for the metabolism of the INSTIs cabotegravir and raltegravir. Drugs that induce or inhibit the UGT enzyme can affect the PK of these INSTIs.